Johnson & Johnson remains a Buy for its stability and consistent dividends, despite short-term price fluctuations and modest growth expectations.

Johnson & Johnson stock (NYSE: JNJ) lost about 7% in 2024, underperforming the broader S&P 500 index, which gained 23% for ...

We recently published a list of Jim Cramer Discussed These 29 Stocks Ahead Of Major AI Event. In this article, we are going ...

NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & ...

A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung ...

Senate Republicans fear that President-elect Trump’s tax agenda could be derailed in the House by several potential landmines ...

In Garvin County, snow and sleet have been falling since early Thursday and KOCO 5 spoke emergency management officials on what they’re seeing.

NAACP President and CEO Derrick Johnson is calling on President Biden to take action on “critical promises” before leaving ...

Dwayne 'The Rock' Johnson outpaces John Cena in earnings with a record-breaking $50 million upfront salary for his role in ...

Anti-aging advocate Bryan Johnson, who gulps down 54 pills for breakfast, recently discovered a wrinkle in his meticulous ...

Johnson & Johnson has won Food and Drug Administration priority review for its application seeking approval of nipocalimab in certain patients with generalized myasthenia gravis.

Johnson & Johnson said on Wednesday it has temporarily paused the rollout of its Varipulse heart device in the United States, ...